P1, N=36, Not yet recruiting, Impact Biotech Ltd | Trial completion date: Dec 2026 --> Dec 2027 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Mar 2025 --> May 2026
9 months ago
Trial completion date • Trial initiation date • Trial primary completion date
P1, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Completed --> Active, not recruiting | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
11 months ago
Enrollment closed • Trial completion date • Trial primary completion date
P1, N=12, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Completed --> Active, not recruiting | Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2025
over 1 year ago
Enrollment closed • Trial completion date • Trial primary completion date
We investigated whether sequential delivery of 3x5 Gy FRT followed by VTP (at 7-9 mg/kg WST-11) 7 days later improved tumour control compared to monotherapy with FRT or VTP alone...Further research aims to identify potential mechanisms of co-operation between these two treatments, with the aim of harnessing anti-tumour immunological responses. Impact statement This pre-clinical data provides first proof-of-concept for this multi-modality treatment, and may help to inform the design of future early phase clinical trials.
3 years ago
Preclinical
|
CD31 (Platelet and endothelial cell adhesion molecule 1)
A mouse orthotopic bladder urothelial model via injection of MB-49 cell line is feasible and displays a very high tumor take rates. Intermittent VTP treatment has an effect on mouse bladder tumors as shown by the decrease in tumor size, weight and change in histology. Additional refinement to the model may provide a means to establish an appropriate timeline and utility for future studies.
over 3 years ago
Preclinical
|
CD31 (Platelet and endothelial cell adhesion molecule 1)